Results 121 to 130 of about 867,189 (360)

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Critical role of the gut microbiota in immune responses and cancer immunotherapy

Journal of Hematology & Oncology
The gut microbiota plays a critical role in the progression of human diseases, especially cancer. In recent decades, there has been accumulating evidence of the connections between the gut microbiota and cancer immunotherapy. Therefore, understanding the
Zehua Li, Weixi Xiong, Zhu Liang, Jinyu Wang, Ziyi Zeng, D. Kołat, Xi Li, Dong Zhou, Xuewen Xu, Linyong Zhao   +9 more
semanticscholar   +1 more source

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Science, 2018
Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies and is rarely accessible to the scientific community at large.
R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, Xinwei Sher, Xiao-Qiao Liu, Hong-Chao Lu, M. Nebozhyn, Chun-Sheng Zhang, J. Lunceford, A. Joe, Jonathan C. Cheng, A. Webber, N. Ibrahim, E. Plimack, P. Ott, T. Seiwert, A. Ribas, T. Mcclanahan, J. Tomassini, A. Loboda, D. Kaufman   +23 more
semanticscholar   +1 more source

B cells are associated with survival and immunotherapy response in sarcoma

Nature, 2020
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade ...
F. Petitprez, A. de Reyniès, E. Keung, T. Chen, Cheng-Ming Sun, J. Calderaro, Y. Jeng, Li-Ping Hsiao, L. Lacroix, A. Bougoüin, M. Moreira, Guillaume Lacroix, Ivo Natario, J. Adam, C. Lucchesi, Y. Laizet, M. Toulmonde, M. Burgess, V. Bolejack, D. Reinke, K. Wani, Wei-Lien Wang, A. Lazar, C. Roland, J. Wargo, Antoine Italiano, C. Sautès-Fridman, H. Tawbi, W. Fridman   +28 more
semanticscholar   +1 more source

Immunotherapy of melanoma

European Journal of Cancer Supplements, 2013
Melanoma is considered one of the immunogenic - if not the most immunogenic - malignancies. This is based on several observations.1.Spontaneous remissions occur occasionally.2.In about 5% of melanomas no primary tumour is found. The genetic aberrations of these tumours closely resemble those of cutaneous melanomas, and therefore are suggestive of ...
openaire   +2 more sources

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Tumor immunotherapy, an innovative anti-cancer therapy, has showcased encouraging outcomes across diverse tumor types. Among these, the PD-1/PD-L1 signaling pathway is a well-known immunological checkpoint, which is significant in the regulation of ...
J. Cui, Yao-Hui Li, Yang Yang, Hai-Kui Yang, Jiaxuan Dong, Zhi Xiao, Xin He, Jia-Hao Guo, Rui-qi Wang, Bo Dai, Zhi-Ling Zhou   +10 more
semanticscholar   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

The Immunotherapy Roadmap [PDF]

Clinical Cancer Research, 2016
Abstract As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations. Clin Cancer Res; 22(2); 275–6. ©2015 AACR.
openaire   +2 more sources